证券代码：300142 证券简称：沃森生物 公告编号：2024-076 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）分别于 2024 年 3 月 29 日和 4 月 19 日召开第五届董事会第十六次会议和 2023 年年度股东大会，审 议通过了《关于变更回购股份用途并注销及减少公司注册资本的议案》，同意公 司对 2023 年已回购股份的用途进行变更，回购股份用途由"用于实施员工持股 计划或股权激励计划"变更为"用于注销并相应减少注册资本"，即对回购专用 证券账户中 2023 年已回购的 2,000,000 股公司股份进行注销并相应减少公司的 注册资本，股东大会授权公司经营管理层办理股份注销及减少公司注册资本的相 关手续。 2024 年 4 月 25 日、7 月 8 日，公司分别召开第五届董事会第十八次会议和 第五届董事会第二十次会议，并于 7 月 26 日召开了 2024 年第一次临时股东大 会，审议通过了《关于变更回购股份用途并注销及减少公司注册资本的议案》和 《关于修订<公司章 ...

证券代码：300142 证券简称：沃森生物 云南沃森生物技术股份有限公司投资者关系活动记录表 编号：2024-010 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|------------------------| | 投资者关系活动 类别 | □ 特定对象调研 □ \n□ 媒体采访 □ □ 新闻发布会 √ □ 现场参观 □ 其他（ ） 中欧基金管理有限公司 | 分析师会议 \n业绩说明会 路演活动 赵磊 | | | 参与单位名称及 人员姓名 | 上海拓聚投资管理有限公司 光大证券自营 刘勇 真灼资本 胡 ...

Group 1: HPV Vaccine Pricing and Market Strategy - The self-paid market price of the bivalent HPV vaccine has been affected by the reduced bid price in the welfare project, while the overall price of other HPV vaccines is expected to remain stable [1] - The company's pricing model considers the pricing and sales of similar products upon listing, disposable income of the target demographic, and competitive pricing of other products [1] - The company aims to maintain an orderly market price system while ensuring reasonable product pricing and leveraging product advantages and brand image [1] Group 2: International Market Expansion and Revenue Growth - The company is actively engaging with multiple potential countries and maintaining close communication with UNICEF and other UN agencies to expedite the overseas export of the bivalent HPV vaccine [2] - In 2023, the company's overseas sales revenue accounted for 22% of the total national vaccine export amount, focusing on rapidly growing regions such as Southeast Asia, the Middle East, North Africa, and South America [2] - The company plans to explore new cooperation models to enhance its position and influence in the international market [2] Group 3: Future Product Development - The company's product development strategy will be dynamically adjusted based on market competition and macroeconomic changes, focusing on upgrading existing products and new product layouts based on mRNA and recombinant protein technologies [2]

Group 1: Financial Performance and Projections - The company anticipates a total export revenue of approximately 549 million, which includes 300 million and 249 million from signed domestic vaccine sales contracts expected to settle in the second half of 2024 [2] - The company has signed contracts that may confirm 249 million in revenue in 2024 [1] - The company reported a decrease in revenue attributed to changes in the age structure and consumption habits of the domestic vaccination population, leading to increased competitive pressure [2] Group 2: Vaccine Development and Market Strategy - The company is actively pursuing the development of a 9-valent HPV vaccine, with ongoing Phase III clinical trials currently in the data analysis and report writing stage [2] - The company has exported vaccine products to 20 countries, covering regions such as Southeast Asia, South Asia, Central Asia, Africa, and the Americas [2] - The company is focusing on the development of mRNA vaccines, including a new COVID-19 vaccine targeting variants like Omicron XBB and EG.5, and is also working on a JN.1 variant vaccine [4] Group 3: Investor Relations and Communication - The company emphasizes the importance of clear communication with investors regarding the progress of vaccine development and market strategies [3] - The company acknowledges the need for transparency about the challenges faced in clinical trials and market competition [3] - The company is committed to maintaining close communication with regulatory bodies to expedite the clinical research of its products [4]

证券代码：300142 证券简称：沃森生物 公告编号：2024-068 云南沃森生物技术股份有限公司 第五届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届监事会第十七 次会议于 2024 年 8 月 26 日在公司会议室召开，会议通知于 8 月 20 日以电子邮 件方式发出。本次会议以现场会议结合通讯表决的方式召开，应参加会议监事 3 人，实际参加会议监事 3 人。会议由监事会主席丁世青女士主持。本次会议的召 集、召开符合《公司法》及《公司章程》的规定。 二、监事会会议审议情况 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案获得通过。 公司《2024 年半年度报告》及《2024 年半年度报告摘要》详见证监会指定 的创业板信息披露网站巨潮资讯网。 2、审议通过了《关于<2024 年上半年募集资金存放与实际使用情况专项报告> 的议案》 监事会审议了公司《2024 年上半年募集资金存放与实际使用情况专项报 告》，监事会认为：公司严格按照《深圳证券 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with total revenue reaching CNY 1.2 billion, representing a growth of 25% compared to the same period last year[8]. - The company's operating revenue for the reporting period was ¥1,433,348,556.33, a decrease of 33.88% compared to the same period last year[13]. - The net profit attributable to shareholders was ¥170,560,456.72, down 62.53% year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥145,990,463.22, a decline of 65.39% compared to the previous year[13]. - The net cash flow from operating activities was ¥90,596,392.55, representing a decrease of 76.51% year-on-year[13]. - The gross profit margin for the first half of 2024 was reported at 60%, a slight decrease from 62% in the previous year due to increased raw material costs[8]. - The management has provided a revenue guidance of CNY 2.5 billion for the full year 2024, indicating a growth target of 20%[8]. - The net profit for the first half of 2024 was CNY 257,516,127.05, a decline of 54.2% from CNY 562,549,133.38 in the first half of 2023[159]. - The company's total liabilities decreased to CNY 158,612,593.59 from CNY 210,655,883.96, reflecting a reduction of 24.7%[156]. Market Expansion and Strategy - The company plans to expand its market presence by entering two new provinces by the end of 2024, aiming for a 10% increase in market share[8]. - The company is actively pursuing strategic partnerships for potential mergers and acquisitions to enhance its product portfolio and market reach[8]. - The company is focusing on market expansion and new product development to enhance future growth prospects[158]. - Watson Bio achieved overseas business revenue of 288 million yuan in 2023, accounting for nearly 22% of the total domestic vaccine exports[30]. - The company has exported vaccine products to 20 countries and regions and is actively pursuing product registration in 23 additional countries and regions[33]. Research and Development - Research and development expenses increased by 20% to CNY 150 million, focusing on new vaccine technologies and product lines[8]. - The company has initiated the development of a new mRNA vaccine targeting emerging COVID-19 variants, with expected completion by Q4 2024[8]. - The company’s R&D pipeline reached a record high of 22,825 projects, with a year-on-year growth of 7.20%[20]. - The company is advancing several innovative vaccines, including the ACYW135 meningococcal polysaccharide conjugate vaccine, which is in phase III clinical trials, and the nine-valent HPV vaccine, also in phase III[37]. - The company has established a mature bacterial vaccine technology platform and a recombinant protein vaccine technology platform, while also developing mRNA and recombinant adenovirus vaccine technology platforms[35]. Environmental and Social Responsibility - The company has implemented multiple environmental protection measures in compliance with national and local regulations[93]. - The company donated approximately 155,000 doses of the bivalent human papillomavirus vaccine (Wozhehui) from January to July 2024 as part of its social responsibility initiatives[107]. - The company adheres to strict environmental protection laws and integrates sustainable development into its operational practices, aiming for a balance between corporate growth and environmental stewardship[105]. - The company has established a comprehensive environmental management system to monitor and minimize its operational impact on the environment[105]. Governance and Compliance - The company has strengthened its internal control and risk management systems, revising multiple governance documents to ensure compliance and effective management of major events[43]. - The company is committed to complying with heightened regulatory standards in the pharmaceutical industry to mitigate policy risks[83]. - The company emphasizes the protection of shareholder rights by ensuring equal access to information and conducting shareholder meetings in compliance with legal regulations[104]. - The company has established a compliance management system focusing on risk management and compliance supervision, enhancing its operational standards[53]. Shareholder and Financial Policies - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[2]. - The company has committed to a cash dividend policy of at least 30% of the distributable profits achieved annually, ensuring reasonable returns to investors[110]. - The company reported no violations regarding external guarantees during the reporting period[112]. - The company has maintained a stable profit distribution policy, prioritizing cash dividends when conditions allow[110]. Financial Position and Assets - The total assets of the company as of June 30, 2024, were CNY 3.5 billion, reflecting a 12% increase from the previous year[8]. - The total assets amounted to CNY 15,086,252,705.73, down from CNY 15,588,869,273.40, indicating a decline of about 3.22%[152]. - Cash and cash equivalents at the end of the reporting period amounted to ¥3,334,740,632.67, representing 22.10% of total assets, a decrease of 5.90% from the previous year[59]. - The company’s total equity attributable to shareholders of the parent company rose to CNY 9,503,843,180.38 from CNY 9,349,276,209.07, an increase of approximately 1.65%[153]. Risks and Challenges - The company faces risks related to accounts receivable due to long payment cycles from government-funded vaccine purchases, which could impact cash flow[82]. - The company is addressing increasing market competition by accelerating new product development and enhancing product quality to maintain market share[83]. - The company has implemented a risk management department to identify, prevent, and control production and quality management risks, particularly for biological products[85].

云南沃森生物技术股份有限公司 子公司管理制度 云南沃森生物技术股份有限公司 子公司管理制度 第一章 总 则 第一条 为加强对云南沃森生物技术股份有限公司（以下简称"公司"或 "本公司"）子公司的管理，有效控制经营风险，保护投资者合法权益，根据 《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证 券法》《深圳证券交易所创业板股票上市规则》（以下简称"《上市规 则》"）《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等法律、法规、部门规章、规范性文件及《云南沃森生物技术股份有 限公司章程》（以下简称"《公司章程》"）的有关规定，结合公司的实际情 况，制定本制度。 第二条 本制度所称子公司是指公司依法设立的，具有独立法人资格的公司 及其控制的下属公司。具体包括： （一）公司独资设立的全资子公司； （二）公司与其他单位或自然人共同出资设立的，公司持有其 50％以上股 份的公司； （三）公司与其他单位或自然人共同出资设立的，公司虽持有其股份低于 50%，但能够决定其董事会半数以上成员组成的企业； （四）公司与其他单位或自然人共同出资设立的，公司虽持有其股份低于 50%，但通过协 ...

证券代码：300142 证券简称：沃森生物 公告编号：2024-073 云南沃森生物技术股份有限公司 关于子公司向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）于 2024 年 8 月 26 日 召开第五届董事会第二十三次会议和第五届监事会第十七次会议，审议通过了 《关于子公司向银行申请综合授信额度的议案》。子公司玉溪沃森生物技术有限 公司（以下简称"玉溪沃森"）和玉溪泽润生物技术有限公司（以下简称"玉溪 泽润"）根据业务发展需要，拟向云南红塔银行股份有限公司（以下简称"红塔 银行"）、中国农业银行股份有限公司玉溪红塔支行（以下简称"农业银行"）、 交通银行股份有限公司玉溪分行（以下简称"交通银行"）申请综合授信额度， 详细情况如下： 一、向银行申请综合授信额度概述 为保障子公司玉溪沃森、玉溪泽润研发、生产、销售及日常运营资金需求， 扩宽公司融资渠道，玉溪沃森、玉溪泽润拟向红塔银行、农业银行、交通银行申 请综合授信额度，综合授信可用于玉溪沃森、玉溪泽润研发、生产、销售及日常 经营支出 ...

云南沃森生物技术股份有限公司 2024 年上半年募集资金存放与实际使用情况专项报告 云南沃森生物技术股份有限公司 2024 年上半年募集资金存放与实际使用情况 专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、募集资金基本情况 1、募集资金金额及到位情况 经中国证券监督管理委员会《关于核准云南沃森生物技术股份有限公司向新余方略知润 投资管理中心（有限合伙）发行股份购买资产并募集配套资金的批复》（证监许可〔2016〕［111］ 号），同意公司向新余方略知润投资管理中心（有限合伙）发行 68,577,982 股股份，用于购 买新余方略知润投资管理中心（有限合伙）所持有的嘉和生物药业有限公司（以下简称"嘉和 生物"）15.45%股权和上海泽润生物科技有限公司（以下简称"上海泽润"）33.53%股权；同 意公司非公开发行股份募集配套资金，本次发行募集资金总额不超过 59,800 万元，发行对象 以现金方式认购。公司此次向特定对象非公开发售的人民币普通股股票每股面值人民币 1 元， 发行数量 64,859,002 股，发行价格为每股人民币 9.22 元，募集 ...

专利证书号：第7323099号 证券代码：300142 证券简称：沃森生物 公告编号：2024-075 云南沃森生物技术股份有限公司 关于公司收到发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）于近日收到由中华人 民共和国国家知识产权局颁发的一项发明专利证书，具体情况如下： 发明名称：一种包裹核酸药物的多肽递送系统及其应用 专利号：ZL 2023 1 0632432.3 特此公告。 云南沃森生物技术股份有限公司 董事会 专利类型：发明专利 专利申请日：2023年5月31日 专利权人：云南沃森生物技术股份有限公司 专利权期限：20年，自专利申请日起算。 专利要点：本发明公开了一种包裹核酸药物的多肽递送系统及其应用。所述 多肽递送系统中多肽结构为KW多肽、KHW多肽、KKK‑KW多肽或者KKK‑KHW 多肽。本发明提供的多肽递送系统中多肽由天然氨基酸组成，可以在细胞内进行 生物降解，不会对目标细胞造成损伤，保证给药的安全性；可与RNA通过静电和 氢键的相互作用缠绕，从而组装成包裹RNA的纳米颗粒， ...